SLC13A5 Inhibitor Program
Metabolic Diseases (NAFLD/NASH, CKD, Diabetes, Obesity)
Pre-clinicalActive
Key Facts
Indication
Metabolic Diseases (NAFLD/NASH, CKD, Diabetes, Obesity)
Phase
Pre-clinical
Status
Active
Company
About Eternygen
Eternygen is a private, preclinical-stage German biotech pioneering a novel approach to treating widespread metabolic and age-related diseases by targeting the SLC13A5 citrate transporter. The company leverages a virtual R&D model, collaborating with a network of academic scientists and CROs to advance its pipeline. With a focus on conditions like NAFLD/NASH, chronic kidney disease, diabetes, and osteoporosis, Eternygen aims to address significant unmet medical needs through a first-in-class mechanism. Its progress is evidenced by recent high-profile scientific publications and presentations at major conferences.
View full company profile